Tezepelumab, apart from reducing all T2-high biomarkers, and thus blood eosinophils, FeNO, and IgE, demonstrated efficacy in severe asthma with not remarkably high T2 biomarkers (T2 low asthma), but still to a lesser extent compared to T2-high asthma [53,54]. The gene discussed is IGHE; the disease is asthma.